Royalty Pharma plc

RPRXNASDAQHealthcare● Active

$56.33

+$0.46(+0.82%)

Market Cap$24.2B

P/E Ratio—

52W High$56.07

52W Low$33.37

Avg Volume3.6M

Open$56.00

Beta0.42

Free Cash Flow Financials Revenue

Royalty Pharma plc (RPRX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

RPRX · free cash flow · updated Jun 8, 2026

Core FCF metrics

RPRX · FCF · TTM · margin & CAGR

Free cash flow was $2.49B for FY2025 (fiscal year ending 2025-12-31), down 10.1% year-over-year The FCF margin was 104.7%. Five-year CAGR stands at +4.1%.

FY2025 Free Cash Flow$2.49B▼ -10.1% YoY

Trailing 12M (TTM)$2.65Btrailing 4 quarters sum

FCF Margin104.7%$2.49B ÷ revenue

3-Year CAGR+5.1%FY2022 → FY2025

5-Year CAGR+4.1%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

RPRX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$2.49B(0M)$2.49B▼ 10.1%104.7%

FY2024$2.77B(0M)$2.77B▼ 7.3%122.3%

FY2023$2.99B(0M)$2.99B▲ +39.4%126.9%

FY2022$2.14B(0M)$2.14B▲ +6.3%95.8%

FY2021$2.02B(0M)$2.02B▼ 0.8%88.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

RPRX · P/FCF · FCF yield · FCF per share

Royalty Pharma plc (RPRX) trades at a FCF yield of 10.96% and a price-to-free-cash-flow ratio of 9.2x. FCF per share stands at $6.15, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

10.96%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$6.15

TTM FCF ÷ Shares Outstanding

Price / FCF

x9.2

Share Price ÷ FCF per Share

EV / FCF (TTM)

x12.3

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

RPRX · cash flow statement · operating / investing / financing

For FY2025, Royalty Pharma plc generated $2.49B in operating cash flow and spent 0M in capital expenditures, yielding $2.49B in free cash flow.

Operating Activities

+$2.49B

Cash from core business operations

2025-12-31

Investing Activities

−$1.61B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$1.19B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($2.49B) − |CapEx| (0M) = FCF ($2.49B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

RPRX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Royalty Pharma plcYOU

RPRX

$2.49B-10.1%104.7%

13%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Royalty Pharma plc (RPRX) reported free cash flow of $2.49B for FY2025 (fiscal year ending 2025-12-31), down 10.1% year-over-year. The FCF margin was 104.7%.

Based on available data, Royalty Pharma plc has maintained positive free cash flow for at least 9 fiscal year(s). FCF peaked at $2.99B in FY2023. The 5-year CAGR stands at +4.1%.

Royalty Pharma plc's FCF yield is 10.96% and price-to-FCF ratio is 9.2x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

RPRX free cash flow · 8 questions

Royalty Pharma plc free cash flow was $2.49B for FY2025, down 10.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $2.65B.

RPRX free cash flowRPRX FCFRPRX FCF 2025RPRX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Royalty Pharma plc · Royalty Pharma plc SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026